7Seas cancer claims attract FDA attention
This article was originally published in The Tan Sheet
Executive SummarySupplement claims made by 7Seas LLC on Web sites such as 1www.AlternateCancerCure.com and 2www.TreatAllCancer.com elicit an April 5 warning letter from FDA's Florida District office. The letter to Norman Hem of the Hialeah, Fla.-based firm alleges that products, including Jade Windscreen, Apricot Seeds and Miracle Mineral Supplement, make disease claims causing them to be unapproved drugs. According to the agency, 7Seas' claims include, "The most powerful, PROVEN cancer treatment and prevention products EVER known to humankind" and "MMS is the answer to ... malaria, hepatitis A, B and C, colds, herpes, TB, most cancer, flu, pneumonia, as well as many other illnesses and diseases." The firm had 15 days to respond to FDA
You may also be interested in...
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
The global insulin pump market is expected to see significant growth, reaching $5.1bn by 2023. A new Market Intel story looks at the competitive landscape of the three leading companies in this market, Medtronic, Insulet and Tandem Diabetes Care, which are all expected to launch new products in 2020. See what Viral Shah, an assistant professor of medicine and pediatrics at the University of Colorado, said about the diabetes market here.